Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility
Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a $100 million At-The-Market offering facility (“ATM”).
The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-264189) filed with the Securities and Exchange Commission on April 7, 2022.
Jefferies LLC acted as agent for the ATM.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo and associate Matt Siracusa.
- Sichenzia Ross Ference LLP Joins Cyngn Inc. in Ringing Opening Bell at Nasdaq MarketSite - May 12, 2022
- Gregory Sichenzia of Sichenzia Ross Ference LLP Quoted in Law360’s “IPO Lawyers See Mild Pickup in an Otherwise Cool Spring” - May 5, 2022
- Sichenzia Ross Ference LLP Represents Cyngn Inc. in $20 Million Private Placement Offering - May 2, 2022